Skip to main content
All lobbying filings

THE HEALTH EQUITY STRATEGIES GROUP, LLC

THE HEALTH EQUITY STRATEGIES GROUP, LLC filed a Q1 report for TRAVERE THERAPEUTICS on May 19, 2026, reporting $16,000 in lobbying income.

Lobbying for TRAVERE THERAPEUTICS · Pharmaceutical company

All filings by THE HEALTH EQUITY STRATEGIES GROUP, LLC · Everything TRAVERE THERAPEUTICS has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted May 19, 2026
Income
$16,000
What the client paid this registrant for the period.
Client based in
California

Official filing document

 Government bodies contacted 1

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 4
Health Issues

Rare kidney disease

Medical/Disease Research/Clinical Labs

Rare kidney disease

Medicare/Medicaid

Rare kidney disease

Pharmacy

Rare kidney disease

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem